GSK's optimistic long-term outlook is driven by the expected...

GSK's optimistic long-term outlook is driven by the expected launch of at least 12 major products from 2025 in infectious, respiratory disorders and cancer areas. The company's performance and future outlook could suggest a positive trend for the stock.